The Pharmacodynamics of Parenteral Glycoprotein IIb/IIIa Inhibitors
Open Access
- 1 February 2002
- journal article
- review article
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 15 (1) , 45-60
- https://doi.org/10.1111/j.1540-8183.2002.tb01034.x
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trialThe Lancet, 2001
- Development of eptifibatideAmerican Heart Journal, 1999
- Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb–IIIaClinical Therapeutics, 1999
- Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplastyJournal of the American College of Cardiology, 1996
- Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary interventionThe American Journal of Cardiology, 1995
- Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)The American Journal of Cardiology, 1995
- Abciximab (c7E3 Fab)Drugs, 1994
- Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibodyThe American Journal of Cardiology, 1993
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- The Interaction of von Willebrand Factor and the Platelet Glycoprotein Ib-IX ComplexPlatelets, 1990